Cardiol Therapeutics reaches new milestone in Phase II study for recurrent pericarditisProactive Investors • 11/01/23
Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent PericarditisNewsfile Corp • 11/01/23
Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementNewsfile Corp • 10/20/23
Cardiol Therapeutics says study results show positive effects of subcutaneously administered cannabidiolProactive Investors • 10/10/23
Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection FractionNewsfile Corp • 10/10/23
Cardiol Therapeutics to Present at Cantor Fitzgerald 2023 Global Healthcare ConferenceNewsfile Corp • 09/26/23
Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 09/19/23
Cardiol Therapeutics on track to complete enrollment for acute myocarditis trial six months ahead of scheduleProactive Investors • 09/19/23
Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute MyocarditisNewsfile Corp • 09/19/23
Cardiol Therapeutics Inc. (CRDL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Zacks Investment Research • 09/13/23
Cardiol Therapeutics Inc. (CRDL) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 08/16/23
Cardiol Therapeutics to Present at Canaccord Genuity 43rd Annual Growth ConferenceNewsfile Corp • 08/09/23
Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 p.m. EDTNewsfile Corp • 06/27/23
Cardiol Therapeutics earns higher price target from broker as it ends 1Q with sufficient cash to advance CardioRx candidateProactive Investors • 05/23/23
Cardiol Therapeutics offers an update on operations as it advances the development of its lead drug candidate CardiolRxProactive Investors • 03/29/23
Cardiol Therapeutics says new study results highlight the cardioprotective effects of cannabidiolProactive Investors • 03/07/23
Cardiol Therapeutics Announces Study Results from Collaborating Research Center Demonstrating Cardioprotective Effects of Cannabidiol in a Model of Heart FailureNewsfile Corp • 03/07/23
Cardiol Therapeutics enrolls first patient in Phase II CardiolRx study on recurrent pericarditisProactive Investors • 01/17/23
Cardiol Therapeutics Announces First Patient Enrolled in Phase II Study Evaluating CardiolRx(TM) for the Treatment of Recurrent PericarditisNewsfile Corp • 01/17/23
Cardiol Therapeutics kicks off a multi-center Phase II pilot study of CardiolRx for the treatment of recurrent pericarditisProactive Investors • 12/12/22
Cardiol Therapeutics Commences Multi-Center Phase II Pilot Study of CardiolRx(TM) for the Treatment of Recurrent PericarditisNewsfile Corp • 12/12/22